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Abstract
Aims/hypothesis Oral administration of antigen can induce immunological tolerance. Insulin is a key autoantigen in childhood
type 1 diabetes. Here, oral insulin was given as antigen-specific immunotherapy before the onset of autoimmunity in children
from age 6 months to assess its safety and immune response actions on immunity and the gut microbiome.
Methods A phase I/II randomised controlled trial was performed in a single clinical study centre in Germany. Participants were
44 islet autoantibody-negative children aged 6 months to 2.99 years who had a first-degree relative with type 1 diabetes and a
susceptibleHLADR4-DQ8-containing genotype. Children were randomised 1:1 to daily oral insulin (7.5mgwith dose escalation
to 67.5 mg) or placebo for 12 months using a web-based computer system. The primary outcome was immune efficacy pre-
specified as induction of antibody or T cell responses to insulin and measured in a central treatment-blinded laboratory.
Results Randomisation was performed in 44 children. One child in the placebo group was withdrawn after the first study visit and
data from 22 insulin-treated and 21 placebo-treated children were analysed. Oral insulin was well tolerated with no changes in
metabolic variables. Immune responses to insulin were observed in children who received both insulin (54.5%) and placebo
(66.7%), and the trial did not demonstrate an effect on its primary outcome (p = 0.54). In exploratory analyses, there was
preliminary evidence that the immune response and gut microbiome were modified by the INS genotype Among children with
the type 1 diabetes-susceptible INS genotype (n = 22), antibody responses to insulin were more frequent in insulin-treated
(72.7%) as compared with placebo-treated children (18.2%; p = 0.03). T cell responses to insulin were modified by treatment-
independent inflammatory episodes.
Conclusions/interpretation The study demonstrated that oral insulin immunotherapy in young genetically at-risk children was
safe, but was not associated with an immune response as predefined in the trial primary outcome. Exploratory analyses suggested
that antibody responses to oral insulin may occur in children with a susceptible INS genotype, and that inflammatory episodes
may promote the activation of insulin-responsive T cells.
Trial registration Clinicaltrials.gov NCT02547519
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Introduction
Type 1 diabetes results from an autoimmune destruction of
insulin-producing beta cells in the pancreatic islets of
Langerhans, and is characterised by circulating islet autoanti-
bodies to beta cell antigens [1, 2]. Insulin is a key early
autoantigen in childhood diabetes [3, 4]. Autoimmunity
against insulin often appears in genetically susceptible chil-
dren aged 9 months to 3 years, with a peak incidence at 9–
12 months of age [5–7], and this loss of immune tolerance to
insulin often leads to type 1 diabetes [8, 9]. Immune tolerance
to insulin is influenced by the HLA DRB1*04-DQB1*0302
haplotype [8] and allelic variations in INS, the gene that
encodes insulin [10–12], via mechanisms involving thymic
T cell deletion [13, 14].
Controlled exposure to antigen leads to protection against
immune-mediated diseases such as childhood allergy [15] and
in animal models of autoimmunity [16]. In type 1 diabetes,
attempts have been made to reduce disease risk in individuals
with established autoimmunity by administration of
autoantigen orally [17, 18], intranasally [19, 20], intravenous-
ly or subcutaneously [21, 22]. Treatment-associated immune
effects such as increases in antibody titres [20–22] and chang-
es in CD4+ T cell responses to administered autoantigen were
observed in some of these studies [20], indicating that admin-
istration could lead to immune modulation. Although none of
these trials achieved their primary outcomes of diabetes
prevention, beneficial treatment effects were observed in
exploratory analyses of subgroups within the oral insulin
immunotherapy trials [17, 18].
We reasoned that, similar to peanut allergy [15], the effica-
cy of antigen-specific immune therapy to prevent autoimmune
disease would improve if treatment was started early in life
and as a primary prevention therapy before individuals
become autoantibody positive [23]. We previously demon-
strated that daily oral administration of high doses (67.5 mg)
of insulin to children with a genetic risk of type 1 diabetes did
not induce unwanted hypoglycaemia and was associated with
the induction of low-affinity antibodies against insulin and
insulin-responsive CD4+ T cells with features of regulation
[24]. These treatment-associated immune responses were not
typical of autoimmune diabetes [8, 25]. We, therefore,
inferred that the treatment was likely to be safe and capable
of inducing an immune response that might protect against the
development of type 1 diabetes. While these earlier findings
are an important proof of concept, they were obtained in a
small number of children aged 2–7 years, which is after the
period of greatest susceptibility to insulin autoimmunity and,
therefore, late for primary prevention of islet autoimmunity.
Here, we report the Pre-POInT-early RCT in children aged
6 months to 2 years, which represents the first intervention
with autoantigen at this very early age and, therefore, uniquely
analyses overall safety, immune responses and effects of
exposure to exogenous autoantigen during peak susceptibility.
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Children in this age group undergo a transition from mater-
nally derived immunity to acquired protection through expo-
sure to vaccinations and infectious agents [26], and large
changes in the immune repertoire and the gut microbiome.
Daily exposure of the mucosal immune system to a key
autoantigen in genetically susceptible children during this
period presents a rare opportunity to assess the interplay
between these factors in eliciting immune responses.
The Pre-POInT-early trial had four objectives. First, to
determine the safety of daily oral insulin administration in
very young children with high genetic susceptibility for type
1 diabetes; second, to determine whether the previously
observed antibody and CD4+ T cell responses to oral insulin
could be observed in younger children; third, to explore inter-
actions between oral insulin therapy and INS genotype and
microbiome; and, fourth, to investigate immune changes and




The Pre-POInT-early study was a randomised, placebo-
controlled, double-blind, single-centre, pilot phase II clinical
study (Clinicaltrials.gov registration no. NCT02547519).
Participants were recruited between December 2015 and
December 2016. Follow-up visits were completed in
December 2017. Children were eligible if they were aged
6 months to 2.99 years; seronegative for autoantibodies to
insulin (IAA), GAD (GADA), insulinoma-associated antigen
2 (IA-2A) and zinc transporter-8 (ZnT8A); and at high genetic
risk of developing type 1 diabetes. High genetic risk was
defined by a first-degree relative with type 1 diabetes diag-
nosed before age 40 years and an HLA genotype that included
the HLA DRB1*04-DQB1*0302 or HLA DRB1*04-
DQB1*0304 haplotypes (DR4-DQ8), and did not include
one of the following alleles or haplotypes: DRB1*11,
DRB1*12, DQB1*0602, DRB1*07-DQB1*0303, DRB1*14-
DQB1*0503 . Th e s t udy wa s app roved by t he
Ethikkommission der Fakultät für Medizin der Technischen
Universität München (206/15). The parents or legal guardians
of each child provided written, informed consent before inclu-
sion in the study. The study was performed in compliance
with the current version of the Helsinki declaration.
Intervention and procedures
Children were randomised 1:1 to receive oral insulin or place-
bo daily for a period of 12months, and parents were instructed
how to administer the study drug. Investigators and partici-
pants were masked to treatment allocation. See the electronic
supplementary material (ESM) Methods for further details.
Children in the oral insulin group received 7.5 mg of insulin
for 3 months, then 22.5 mg for 3 months, and finally 67.5 mg
for 6 months (Fig. 1b). Follow-up visits were scheduled at 3,
6, 9 and 12months after starting treatment. Blood samples and
saliva were collected at each visit to determine islet autoanti-
bodies, immune responses to insulin, lymphocyte and mono-
cyte subsets, and salivary IgA antibodies to insulin using radio
binding assays [24, 27–31], dye dilution cell proliferation
assays (ESM Fig. 1) [24] and FACS analyses, respectively
(see ESMMethods). Single-cell gene expression profiles were
obtained for CD4+ T cells responding to insulin (see ESM
Methods). At the baseline, 3 month and 6 month visits, blood
samples were collected before (−10 min) and 30, 60, 90 and
120 min after study drug intake to measure blood glucose,
insulin and C-peptide (see ESMMethods). Blood cell counts,
blood chemistry, electrolytes, IgE and plasma markers of
inflammation were measured at baseline and 12 months (see
ESM Methods). Stool samples were collected to assess the
microbiome at baseline, 6 months and 12 months (see ESM
Methods). The INS genotype of the children was determined
(see ESM Methods). Medication adherence was assessed by
family self-reporting of daily capsule administration using
adherence sheets. Adverse events were recorded throughout
the study (see ESM Methods). Children reached study
endpoint and stopped treatment if they developed persistent
islet autoantibodies (GADA, IA-2A or ZnT8A) or clinical
diabetes. All data except the plasma markers of inflammation
were submitted before the data hard lock which was signed on
18 July 2018. Data were unblinded by the independent study
statistician on 24 July 2018.
Study outcome
The primary immune efficacy outcome was an immune
response to insulin, defined as an increase in any one or more
of the following: serum IgG antibodies to insulin, salivary IgA
antibodies to insulin, serum IAA or a CD4+ T cell response to
insulin. Additional secondary and exploratory outcomes
included the gene expression profile of CD4+ T cells
responding to insulin, the antibody and CD4+ T cell responses
in children with the INS AA genotype, and the stool
microbiome. Post hoc analyses included T lymphocyte and
monocyte subset frequencies, and plasma inflammatory
markers.
Statistics
Sample size The null hypothesis was that the probability of
developing an antibody and/or T cell response to insulin in the
oral insulin group equals the probability of developing an
antibody and/or T cell response in the placebo group. Based
on results of the Pre-Primary Oral Insulin Trial (Pre-POInT)
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study [24], response rates of 20% in the placebo group and
67% in the oral insulin group were assumed. Accordingly,
enrolment and randomisation of 44 children 1:1 to two treat-
ment groups was expected to be sufficient to reject the null
hypothesis with a two-sided Fisher’s exact test at a signifi-
cance level of 0.05 and a power of 80% and 10% dropout.
The sample size estimation was performed using PS Power
and Sample Size Calculations software version 3.0.43 [32].
Statistical comparisons To compare continuous variables
between the two independent groups, we used the Mann–
Whitney U test with normal approximation. The Kruskal–
Wallis test was applied when the number of groups was larger
than two. Differences in categorical variables between the
groups were assessed using Fisher’s exact test. Unless other-
wise indicated, continuous variables are reported as the medi-
an and IQR. Time-to-event variables were summarised using
Kaplan–Meier plots and compared with the logrank test.
Additional analyses compared the immunological outcomes
in children with the INSAA genotype and treatment effects on
the stool microbiome (see ESM Methods). The significance
level of two-sided p values was 0.05 for all statistical tests.
Point estimates are given together with the 95% CIs. The
analysis for this paper was generated using SAS software
9.4 (SAS Institute, Cary, NC, USA), R software (2020);
https://www.R-project.org/), the R software packages
‘vegan’ and ‘ggplot2’ [33, 34] and GraphPad Prism software
7.05 (GraphPad Software, San Diego, California USA).
Results
Participant enrolment and treatment
In total, 172 infants aged 6 months to 2 years with a first-
degree family history of type 1 diabetes were screened (Fig.
22 received placebo
• 19 completed study until Visit 5
• 1 withdrew consent prior to Visit 2
• 1 withdrew consent prior to Visit 5
• 1 reached study endpoint at Visit 4
22 received oral insulin
• 20 completed study until Visit 5
• 1 withdrew consent prior to Visit 5
• 1 reached study endpoint at Visit 3




• 8 islet autoantibody positive
• 10 islet autoantibody negative,
no consent provided
22 included in primary 
outcome analysis



























Fig. 1 Schematics of participant disposition, design and treatment groups. (a) Disposition of the participants. All children had a first-degree family
history of type 1 diabetes. Study endpoint was the development of persistent antibodies to GAD, IA-2 or ZnT8. (b) Study design and treatment groups
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1a). Of these, 54 were eligible based on their HLA DRB1-
DQA1-DQB1 genotype and the lack of islet autoantibodies.
Consent to participate was provided for 44 children (17 girls),
who were randomised at a median age of 1.1 years (IQR, 0.8–
1.7 years). Randomised groups were reasonably balanced
with respect to baseline characteristics (Table 1). All of the
randomised children received at least one dose of their allo-
cated treatment. The cumulative insulin exposure was 66.7,
67.2 and 126.2 months for the 7.5 mg, 22.5 mg and 67.5 mg
doses, respectively (ESM Table 1). One child in the placebo
group was withdrawn before attending the 3 month follow-up
visit; no adverse event reporting or immune data were avail-
able from this child. Median adherence to the allocated treat-
ments was 98.0% for placebo and 96.9% for oral insulin
(ESM Table 1). Of 220 planned study visits, 212 (96.4%)
were completed.
Participant safety
Oral insulin therapy was well tolerated with no evidence of
treatment-related hypoglycaemia. All blood glucose concen-
trations measured within 2 h after the first dose of placebo or
oral insulin, or the first dose after each dose escalation, were
>2.78 mmol/l, except for one instance in a child in the placebo
group (Fig. 2a–d). Blood glucose, insulin or C-peptide values
(ESMTable 2); the insulin/C-peptide ratio (Fig. 2e–g); and the
areas under the concentration–time curves for glucose, insulin
or C-peptide (ESM Table 2) were similar between the placebo
and insulin groups. Persistent GADA, IA-2A or ZnT8A
(study endpoint) developed 6.9 months after randomisation
in one child in the oral insulin group and after 9.5 months in
one child in the placebo group. Blood counts and blood chem-
istry were similar between the two groups (ESM Table 3). A
total of 114 adverse events were reported over a cumulative
exposure period of 21.1 years in 21/21 children in the placebo
group (5.64 events per year), and 181 adverse events were
reported over a cumulative exposure period of 21.7 years in
22/22 children in the oral insulin group (8.38 events per year)
(ESM Table 4). There were six serious adverse events, four in
the oral insulin group and two in the placebo group, none of
which were considered related to the study drug. By system
organ class, the frequency of skin and subcutaneous tissue
disorders was greater in the oral insulin group (12 events in
eight children) than in the placebo group (one event in one
child; p = 0.01; ESM Fig. 2). See the ESM Results for further
details on laboratory findings, adverse events and protocol
adherence.
Immunological response to daily oral insulin
administration
The primary outcome was based on findings from the previ-
ous Pre-POInT trial [24] as a positive antibody or CD4+ T cell
response to insulin. The primary outcome was observed in 26/
43 (60.5%) children at 3 (n = 13), 6 (n = 9) or 9 months (n = 4)
after randomisation (Table 2), including 14/21 (66.7%) in the
placebo group and 12/22 (54.5%) in the oral insulin group
(p = 0.54). The cumulative frequencies of antibody responses
to insulin were 33.4% in the placebo group and 50.4% in the
oral insulin group (p = 0.18; Fig. 3a). Responses included an
increased IgG binding to insulin (seven in placebo group and
nine in oral insulin group) and a salivary IgA response to
insulin (one in placebo group and two in oral insulin group).
The cumulative frequencies of the positive CD4+ T cell
responses to insulin were 38.5% in the placebo group and
18.4% in the oral insulin group (p = 0.15; Fig. 3b). CD4+ T
cell responses to insulin at 12 months were lower in the oral
insulin group (median stimulation index [SI], 0.97; IQR,
0.71–1.21) than in the placebo group (median SI, 1.41; IQR,
0.94–2.2; p = 0.014; Fig. 3c).
In conclusion, the study failed to demonstrate an effect on
its predefined primary outcome. As compared with the previ-
ous Pre-POInT study in older children, the responses to insu-
lin were more frequently observed in the placebo group of this
study (66.7% vs 20% [24]; p = 0.02), but not in the oral insulin
groups (54.5% vs 60%). This suggests frequent activation of
Table 1 Baseline characteristics of children enrolled in the Pre-POInT-
early study
Characteristic Placebo Oral insulin
Participants, n 22 22
Girls, n (%) 10 (45.5) 7 (31.8)
Age, median (IQR); years 1.2 (0.9–1.9) 1.0 (0.8–1.4)
Weight, median (IQR); kg 10.5 (9.3–12.8) 9.6 (8.3–11.7)
Height, median (IQR); cm 78.0 (73.0–87.0) 74.0 (70.0–82.0)













aMultiplex indicates that a child has at least two first-degree relatives with
type 1 diabetes
b x = non-DRB1*03, non-DRB1*04
T1D, type 1 diabetes; VNTR, variable number tandem repeat
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immune responses to insulin in very young genetically
susceptible children in the study.
The INS genotype was associated with immunological
responses to treatment
Autoimmunity against insulin is more frequent in children
with the susceptible INS AA genotype [12, 35]. Therefore,
an exploratory analysis of the immune response to insulin
stratified for INS genotype was included in the study analysis
plan. An antibody response to insulin was observed in 10/22
children with the susceptible INS AA genotype, including
2/11 (18.2%) children in the placebo group and 8/11
(72.7%) children in the oral insulin group (p = 0.03).
Cumulative frequencies of antibody responses at 12 months
were 18.2% (95% CI 0.1%, 40.4%) in placebo and 75.8%
(95% CI 48.8%, 99.9%) in oral insulin groups (p = 0.0085;
Fig. 3d, ESM Table 5). The majority (n = 7) of children with
the susceptible INS AA genotype in the oral insulin group
showed an antibody response by 6 months of treatment. An
interaction between INS genotype and treatment was statisti-
cally tested using the Cox proportional hazards model and was
observed for an antibody response (p = 0.024). Age was
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Fig. 2 Blood glucose concentration and insulin/C-peptide ratio over time.
(a–d) Blood glucose concentrations weremeasured in children before and
after intake of oral insulin at a dose of 7.5 mg at baseline visit 1 (a; n =
22), 22.5 mg at 3 months visit 2 (b; n = 22), and 67.5 mg at 6 months visit
3 (c; n =22), or placebo at visits 1–3 (d; n = 63). The concentrations for
individual children are connected by lines. The dashed line indicates the
threshold for hypoglycaemia at 2.78 mmol/l (a–d). (e–g) The insulin/C-
peptide ratio is plotted for each time point at visit 1 (e), visit 2 (f) and visit
3 (g) for children receiving oral insulin (red triangles) or placebo (blue
circles)
Table 2 Primary outcome







Placebo (n=21) 7 (33.3) 8 (38.1) 14 (66.7)
Oral insulin (n=22) 11 (50.0) 4 (18.2) 12 (54.5)
INS AA genotype (n=22)
Placebo (n=11) 2 (18.2) 5 (45.5) 7 (63.6)
Oral insulin (n=11) 8 (72.7) 4 (36.4) 9 (81.8)
Data are given as n (%)
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(p = 0.032). Unlike the antibody responses, the frequency of T
cell responses to insulin in children with the INSAA genotype
was not different between the placebo group (5/11) and the
oral insulin group (4/11; p > 0.99; ESM Table 5). These
results suggest that oral insulin may induce an antibody
response in very young children with a susceptible INS geno-
type in this study.
Age, INS genotype and treatment are associated with
microbiome alterations
It is assumed that the potentially beneficial effects of oral expo-
sure to antigen are via tolerogenic presentation in the oral
mucosa. We, therefore, included stool collection and planned
and performed separate exploratory and post hoc analyses of
the microbiome in the study participants. There was a marked
relationship between the age of the children and the alpha and
beta diversities of the microbiome. Bacterial richness (observed
operational taxonomic units [OTUs]) and bacterial evenness
(Shannon diversity) increased with age, and bacterial commu-
nity metrics (unweighted Jaccard distance and weighted Bray–
Curtis distance) converged with age (Fig. 4a–d). Similar find-
ings were observed by whole-genome sequencing (ESM Fig.
3a–d). There were significant changes in the abundances of
several phyla and genera over time (ESM Fig. 4a,b).
The alpha and beta diversities of the microbiome were simi-
lar between the oral insulin and placebo groups. However, there
were bacterial community differences between children with
the INS AA genotype and children with the AT or TT geno-
types, and between the treatment groups after stratification by
INS genotype. The unweighted and weighted bacterial commu-
nity metrics differed between children with the INS AA geno-
type and children with the AT or TT genotypes (unweighted
Jaccard distance p = 0.025; weighted Bray–Curtis distance p =
0.042; Fig. 4e,f). The relative abundance of Bacteroides dorei
was increased in children with the INSAA genotype (6.2%) vs
children with the AT or TT genotypes (0.4%; p = 0.002; ESM








































































































































































































Fig. 3 Responses to treatment and analysis of responses. (a, b) Immune
response to oral insulin or placebo. Kaplan–Meier analysis of a positive
antibody response to insulin (a) and CD4+ T cell response to insulin (b) as
defined by the primary outcome criteria in children who received placebo
(blue line; n = 21) or oral insulin (red line; n = 22). The follow-up time is
calculated from the first day of treatment (a, b). (c) CD4+ T cell response
to insulin calculated as the SI relative to medium control at baseline (visit
1) and at 12 months (visit 5) in children who received placebo (blue
circles; n = 21 at baseline, n = 18 at 12months) or oral insulin (red circles;
n = 22 at baseline, n = 18 at 12 months). (d) Kaplan–Meier analysis of a
positive antibody response to insulin as defined by the primary outcome
criteria in children with the INSAA genotype who received placebo (blue
line; n = 11) or oral insulin (red line; n = 11; p = 0.0085)
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INS AA genotype who received oral insulin differed as
compared with the placebo group and with children with the
AT or TT genotypes (p = 0.0069; Fig. 4g). Subtle differences in
alpha diversity were also observed (ESM Fig. 5b,c). There was
also a potential increase in bacterial evenness (Shannon diver-
sity) observed among children with the INS AA genotype who
showed a positive antibody response to insulin compared with
children who showed no antibody response (p = 0.04; Fig. 4h).
Type 1 interferon profiles were frequent and
associated with inflammatory markers and events
The trial included peripheral blood flow analyses. We found
stable cell populations with strong inter-individual differences
(Treg, CD8+ T cells; ESM Fig. 6a,b) and other cell popula-
tions that varied across measurements within children (inter-
mediate monocytes, activated CD8+ T cells; ESM Fig. 6c,d).
Age was strongly correlated with the frequency of peripheral
blood mononuclear cell populations (ESM Fig. 7a,b). We
previously found that the two samples exhibiting CD4+ T cell
responses to insulin among the placebo-treated children in the
Pre-POInT study had evidence of a viral inflammatory
response. We, therefore, performed post hoc analyses in flow
data from the Pre-POInT-early children and frequently
observed samples with CD169 (Siglec-1) expression on
monocytes (59/208, 28.4%; Fig. 5a,b), an indication of an
ongoing type 1 interferon response [36]. This feature was
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Fig. 4 Microbiome alterations in relation to age, INS genotype and treat-
ment. (a, b) Alpha diversity in relation to age over the time of study
participation in samples from baseline (n = 40), 6 months (n = 40) and
12months (n = 35); shown are richness (observed OTU) (a) and evenness
(Shannon) (b). (c, d) Beta diversity in relation to age over time of study
participation (baseline, 6 months, 12 months); shown are Jaccard distance
(c; p < 0.0001) and Bray–Curtis distance (d; p < 0.0001). Each dot repre-
sents the distance between two samples within the age range (c, d). (e–g)
Beta diversity differences by PCoA (baseline, 6 months, 12 months);
shown are Jaccard distance in children with the INSAA genotype (purple
dots and lines) or the INS AT or TT genotype (bright-blue dots and lines)
(e; p = 0.0258), Bray–Curtis distance in children with the INS AA geno-
type (purple dots and lines) or the INS AT or TT genotype (bright-blue
dots and lines) (f; p = 0.0422), and Jaccard distance in children with the
INSAA genotype who received placebo (dark-blue dots and lines) or oral
insulin (red dots and lines), and in children with the INS AT or TT
genotype who received placebo (bright-orange dots and lines) or oral
insulin (fuchsia dots and lines) (g; p = 0.0069). (h) Alpha diversity
(Shannon) in children with the INS AA genotype who had a negative
(n = 22 samples) or positive (n = 4 samples) antibody response to insulin
(6 months, 12 months) (p = 0.0395). Unless indicated, the plots include
both placebo- and oral insulin-treated children. For treatment-related
analyses, only post-baseline samples at 6 and 12 months were included.
Ab, antibody; PC1, principal component 1; PC2, principal component 2;
PCoA, principal coordinates analysis
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samples in 19 (44%) children. Monocyte CD169 expression
was associated with the relative frequency of the inflammato-
ry type intermediate (CD14++CD16+) monocytes (r = 0.52;
p < 0.0001; Fig. 5c), and both of these features were associat-
ed with an increased frequency of activated (CD69+) T cells
(CD169+ monocytes, r = 0.34, p < 0.0001; intermediate
monocytes, r = 0.65, p < 0.0001). In post hoc measurements
of inflammatory proteins, monocyte CD169 expression was
correlated with the levels of the proinflammatory plasma
proteins CXCL10 (r = 0.49; p = 0.0002), IL-6 (r = 0.42; p =
0.0038) and IFNg (r = 0.39; p = 0.0095; ESM Table 6).
Monocyte CD169 expression was also associated with
decreased gut microbiome richness (p = 0.033; ESM Fig.
8a,b) and younger age (p = 0.014; ESMFig. 8c). To determine
whether the monocyte CD169 expression corresponded to
potential inflammatory episodes in the children, we examined
the trial adverse events in the 2 week period before sample
collection and observed more adverse events when samples
were monocyte CD169+ (20/49, 40.8%) than when samples
were CD169− (21/118, 17.8%; p = 0.0028).
Type 1 interferon profiles interacted with INS
genotype to promote CD4+ T cell responses to insulin
We speculated that the remarkably frequent inflammatory
response may play a role in the pathogenesis of insulin auto-
immunity. We found an association between monocyte
CD169 expression and positive CD4+ T cell responses to
insulin (SI > 3; 12/50 CD169+ vs 10/146 CD169−; p =
0.0026), suggesting that the in vitro assay may be affected
by the inflammatory state of the child. The association
between monocyte CD169 expression and T cell responses
to insulin was most evident in children with the susceptible
INS genotype (Fig. 5d). Among children with the INS AA
genotype, CD4+ T cell responses to insulin were observed in
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Fig. 5 T cell responses to insulin in relation to INS genotype and mono-
cyte CD169 expression. (a–d) Monocyte CD169 expression and CD4+ T
cell responses to insulin over the time of study participation (baseline, 3,
6, 9, 12 months) in all study participants. (a) Representative flow cytom-
etry histograms of CD169 staining intensity on monocytes. Shown are
three samples with low (blue; 0.6% positive cells), moderate (light blue,
21.2% positive cells) and high monocyte CD169 expression (red, 99.7%
positive cells). A threshold of >5% positive monocytes was used as the
threshold for defining monocyte CD169+ samples. (b) Percentage of
CD169+ cells out of CD14+ monocytes in relation to age over the time
of study participation in children who received placebo (blue lines; n =
21) or oral insulin (red lines; n = 22); plotted on a log scale. (c)
Correlation between the frequency of CD169+ monocytes and the
frequency of intermediate monocytes in peripheral blood from children
who received placebo (blue circles; n = 102 samples) or oral insulin (red
circles; n = 104 samples; r = 0.52, p < 0.0001). (d) CD4+ T cell responses
to insulin (SI) in samples from 20 children with the INS AT or TT geno-
type and 22 children with the INS AA genotype and stratified by mono-
cyte CD169 expression as negative (CD169neg, grey circles; n = 148
samples) or positive (CD169pos, green circles; n = 58 samples) in all study
visits; plotted on a log scale. (e) The frequencies of insulin-responsive
CD4+ T cells (n = 1036 cells from 22 samples) in the Th1/Th21-like cell
clusters 2 and 3 (left; white bars) and the Treg-like clusters 9, 10 and 11
(right; grey bars) according to whether cells were from children with the
INS AT/TT (n = 550 cells) or INS AA (n = 486 cells) genotype and
samples that were monocyte CD169 negative (n = 559 cells) or positive
(n = 477 cells). **p < 0.01, ***p < 0.001
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(p = 0.0004). No difference was observed between the INS
AA CD169+ and INS AT/TT CD169+ sample groups (p =
0.32). A similar relationship was observed for CD8+ T cells
(ESM Fig. 9). Monocyte CD169 expression was not associat-
ed with antibody responses to insulin.
We also examined single-cell transcription profiles of the
insulin-responsive CD4+ T cells in relation to monocyte
CD169 expression. The expression of 76 genes (ESM
Table 7) was analysed in 1036 insulin-responsive CD4+ T
cells from samples with a >3 SI response to insulin. The
profiles were distributed in 11 cell clusters (ESM Fig. 10a),
including two clusters with features of Th1/Th21-like T cells
(IFNG, IL-21; clusters 2 and 3; n = 184 cells), and three clus-
ters with features of Tregs (FOXP3, low CD127 and low
cytokine expression; clusters 9, 10 and 11; n = 313 cells;
ESM Fig. 10b). The distribution across clusters differed
between cells from CD169+ and CD169− samples (p = 1.5 ×
10−10), between cells from children with the INSAA genotype
and the AT or TT genotypes (p = 4.3 × 10−7), and between the
CD169+ and CD169− samples from children with the INS AA
genotype (p = 0.0003). Among children with the INS AA
genotype, the CD169+ samples contained a higher proportion
of insulin-responsive cells in the Th1/Th21-like clusters (88/
323; 27.2%) than the CD169− samples (28/163, 17.2%; p =
0.0094) and a lower proportion of insulin-responsive cells in
the Treg-like clusters (63/323, 19.5% vs 46/163, 28.2%; p =
0.0028; Fig. 5e). Altogether, these findings suggest that
in vitro presentation of insulin to T cells by antigen-
presenting cells will more likely result in a productive Th1/
Th21-like T cell response if the cells are from a child with a
susceptible INS genotype and in an active inflammatory state.
Discussion
The Pre-POInT-early study is the first to expose very young
genetically at-risk children to exogenous autoantigen at an age
of peak susceptibility to autoimmunity. It demonstrated that
daily oral administration of up to 67.5mg of insulin to healthy,
genetically at-risk, islet autoantibody-negative children at
6 months to 2 years of age was well tolerated without signs
of hypoglycaemia. The study did not demonstrate an effect on
its primary outcome of immune efficacy defined by the find-
ings in older children [24] as either antibody or T cell
responses to insulin. In secondary and exploratory analyses,
treatment effects were, however, found for CD4+ T cell
responses to insulin and in subgroup analyses of children with
the susceptible INS genotype. Post hoc analyses also revealed
remarkably frequent treatment-independent inflammatory
episodes with features of type 1 interferon responses in the
participants. These inflammatory episodes influenced insulin-
directed T cell responses, again in an INS gene-associated
manner, providing a potential mechanism for the high inci-
dence of islet autoimmunity in early childhood.
Although hypoglycaemia was not previously reported
during treatment with oral insulin [17, 18, 24], children
<2 years of age have not been exposed to oral insulin.
Therefore, the absence of hypoglycaemia at any of the tested
doses with a cumulative exposure of >21 years is an important
safety outcome. We also found no differences in glucose,
insulin and C-peptide over a 2 h period after administration
of insulin compared with administration of a placebo. To our
knowledge, this is the first study to include comprehensive
metabolic measures upon administration of oral insulin in all
participating children. These data indicate that oral insulin is
unlikely to enter the blood stream, a conclusion that was
important for initiating the Primary Oral Insulin Trial
(POInT) phase 2b trial in 4–6-month-old infants [37]. Of note,
the induction of tolerance by oral antigen is thought to be via
antigen uptake in the oral and/or gut mucosa and does not
require entry into the blood stream.
As in the Diabetes Prevention Trial–Type 1 (DPT-1) [17],
TrialNet [18] and Pre-POInT [24] trials, we observed no signs
of allergy or intolerance to orally administered insulin. The
frequency of adverse events was not increased in the oral
insulin group, except for skin and subcutaneous tissue disor-
ders. This was not observed in larger secondary prevention
DPT-1 [17] and TrialNet [18] trials, where children from
3 years of age were treated with a daily dose of 7.5 mg of oral
insulin. It is possible that our finding was due to the exposure
of younger children or the use of higher oral insulin doses that
may increase the likelihood of skin exposure to study drug.
The overall frequency of skin and subcutaneous tissue disor-
ders among all reported adverse events (4.3%) is comparable
to that in TrialNet (7.7%) [18]. All skin and subcutaneous
tissue adverse events in our study were classified as mild,
resolved during the course of the study and were not correlat-
ed with other blood chemistry measurements or inflammatory
markers.
In addition to establishing safety, our objective was to find
evidence for a treatment-induced immune response. The study
design and sample size were based on results from the previ-
ous Pre-POInT study, which enrolled children at 2–7 years of
age with greater genetic risk [24]. Using the same outcomes
and measurement methods, we observed a higher overall reac-
tivity to insulin in the placebo group in this study (67%) than
in the previous Pre-POInT study (20%), markedly reducing
the study power. The younger age of the children is a major
difference of the current study and is likely to contribute to the
higher observed frequency of immune responses to insulin in
the placebo group. Evidence for this includes the association
between the antibody responses to insulin and younger age,
and the correlation between age and T cell and monocyte
subset compositions, with the latter being associated with
the T cell responses to insulin.
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Limitations of the study include our misjudgement on the
effect size in favour of oral insulin, leading to the inclusion of
44 children, and the short follow-up period on relatively few
children, which prevented us from assessing the efficacy of treat-
ment in preventing islet autoimmunity or type 1 diabetes. All
participants were of European extraction and the study cannot
assess effects in other racial groups. A strength of the study is
that, despite the challenge of obtaining blood samples from
young children, adherence to the study protocol was high with
comprehensive sample and data collection. These data included
deep phenotyping of the immune responses and microbiome
during early childhood and provided insights into how oral insu-
lin might perturb the immune system and into disease mecha-
nism. As there were no previous data to justify their inclusion in
primary analyses, a number of these findings were based on
exploratory and post hoc analyses, and, therefore, require vali-
dation in subsequent studies such as the POInT trial [37].
A potentially important finding was that the INS genotype
appeared to influence antibody responses to treatment. In partic-
ular, we observed an association between oral insulin and the
antibody response in children with the susceptible INSAAgeno-
type, suggesting that the INS gene may modify the likelihood of
the immune system responding to oral insulin. The response was
observed by 6 months of treatment, corresponding to a 22.5 mg
dose, which is lower than in the previous study [24] and may
reflect the lower body weight of children in the present study.
Genetic susceptibility criteria in the previous study were more
stringent and it is likely that the majority of participants had the
susceptible AA genotype. We also discovered differences in the
microbiome composition between children with susceptible and
non-susceptible INS genotypes and also minor effects after oral
insulin treatment in children with the susceptible INS AA geno-
type. This included differences in bacterial diversity and rich-
ness, and an increased abundance of Bacteroides dorei in chil-
dren with the susceptible INS genotype, a finding that is consis-
tent with the increased abundance of Bacteroides dorei in chil-
dren who developed type 1 diabetes in a Finnish study [38].
Unlike the antibody outcome, the in vitro T cell responses to
insulin were not associated with treatment after stratification by
the INS genotype. The T cell responses were, however, strongly
associated with monocyte CD169 expression, providing new
insights into disease pathogenesis. Monocyte CD169 expression
is a sensitive marker of a type 1 interferon signature, which
increases before islet autoantibody seroconversion in young chil-
dren and is associated with respiratory infection [36]. CD169+
samples were surprisingly frequent and observed in the majority
of children. They were also associated with recent adverse
events, younger age and several other inflammatory markers.
Early infection is associated with islet autoimmunity [39–41]
and type 1 diabetes [42]. Thus, our findings that in vitro T cell
responses to insulin were more likely to occur in CD169+
samples in children with the susceptible INS AA genotype
may be relevant to the mechanism of insulin autoimmunity.
We believe that our results do not reflect the presence of
in vivo-primed T cells, but rather a heightened ability of the
CD169+ monocytes to activate naive T cells in the in vitro assay.
Children with the susceptible INS genotype are expected to have
more peripheral insulin-autoreactive T cells [13, 14]. Extending
our in vitro findings, we suggest that a type 1 interferon response
to infection in antigen-presenting cells in vivo further increases
the likelihood of activating these T cells and eventually leads to
insulin autoimmunity. The observation that the insulin-
responsive cells from the CD169+ samples contained more
Th1/Th21 cells and fewer Tregs supports this hypothesis, and
may also explain our previous finding of proinflammatory,
proinsulin-responsive T cells in infants who later developed islet
autoimmunity [25].
Overall, this study demonstrated safety for high-dose oral
insulin administration in young children. The study did not
reach its primary outcome of immune efficacy. Exploratory
analyses, however, provided evidence of an interaction
between an immune response to treatment and the INS gene
as previously demonstrated for autoantigen. We, therefore,
advocate that ongoing trials that include insulin or peptides
of proinsulin as antigen-specific immunotherapy [43, 44]
should incorporate stratification by INS genotype into their
study design and analyses.
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